昂利康：总计回购约360万股

Group 1 - Company announced a share buyback plan that will expire on November 3, 2025, with a total of approximately 3.6 million shares repurchased, accounting for 1.78% of total share capital [1] - The highest transaction price during the buyback was 17 CNY per share, while the lowest was 12.17 CNY, with a total transaction amount of approximately 50 million CNY [1] - For the first half of 2025, the company's revenue composition is entirely from the pharmaceutical manufacturing industry, with a 100% share [1] Group 2 - The company's market capitalization is currently 8.2 billion CNY [2] - The industry is experiencing a significant increase in overseas orders, with a growth of 246%, covering over 50 countries and regions [2] - Concerns have been raised about potential malicious competition in the industry, as some entities are reportedly selling at a loss [2]